Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 10.64 percent increase over losses of $(0.47) per share from the same period last year.